CTLs are commonly CD8+ and as such are able to recognize the complex comprising the major histocompatibility complex class I (MHC-I) molecule and the tumor antigen peptide on tumor cells, thus stimulating an effective and specific anti-tumor immune response (Ahmed and Bae 2014; Itoh and Shichijo 2005). This evidence concerns the gene CD8A and neoplasm.